{
    "Clinical Trial ID": "NCT00418028",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A (Cint)",
        "  Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity.",
        "INTERVENTION 2: ",
        "  Arm B (Ccont)",
        "  Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity."
    ],
    "Eligibility": [
        "Inclusion Criteria",
        "  Patients diagnosed with metastatic breast cancer",
        "  Patients that either have received previous treatment with anthracyclines and/or taxanes or not (either as advance or in metastatic disease).",
        "  The patient is ambulatory with a functional ECOG < 2 status (see Appendix 2).",
        "  Patient presents, at least one lesion measurable according to RECIST criteria (see Appendix 3)",
        "  Patients with a life expectancy of at least 3 months.",
        "  Patients that agree to and are able to fulfill the requirements of the whole protocol through the whole study.",
        "Exclusion criteria:",
        "  Patients that have previously shown unexpected severe reactions to therapy with fluoropyrimidines or with a known sensitivity to 5-fluorouracile.",
        "  Patients previously treated with capecitabine.",
        "  Patients with organ transplants.",
        "  Other diseases or severe affections:",
        "  Patients with previous convulsions, central nervous system diseases or psychiatric diseases, including dementia, that the investigator might consider clinically significant and which adversely affect therapeutic compliance.",
        "  Patients with severe intellectual impairment, unable to carry out basic daily routines and established depression.",
        "  Clinical significant cardiac disease (e. g. . congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not fully controlled with medication) or myocardial infarction within the last 12 months.",
        "  Severe renal impairment (baseline creatinine clearance < 30 ml/min)",
        "  Patients with signs of metastasis in the CNS. Patients with a history of uncontrolled convulsions, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake should be excluded.",
        "  Patients with an active infection.",
        "  Patients with a history of other neoplasias during the previous five years, except for basal cell skin cancer or cervical cancer in situ, both cured.",
        "  Patients showing the following laboratory values:",
        "  Neutrophil count < 555 x 109/l",
        "  Platelet count< 100 x 109/l",
        "  Serum creatinine > 1,5 x upper normality limit",
        "  seric bilirubin > 2,0 x upper normality limit",
        "  ALAT, ASAT > 2,5 x upper normality limit or > 5 x upper normality limit in case of liver metastases",
        "  Alkaline phosphatase > 2,5 x upper normality limit > 5 x upper normality limit in case of liver metastases o > 10 x upper normality limit in case of bone metastases.",
        "  Patients under radiotherapy four weeks prior to the initiation of the study treatment, or under previous radiotherapy on the marker lesions be measured during the study (new marker lesions that appear in previously irradiated areas are accepted) or patients who are receiving programmed radiotherapy.",
        "  Patients under major surgery within 4 weeks prior to study treatment or who have not completely recovered from the effects of major surgery.",
        "  Patients who lack upper gastrointestinal tract physical integrity or with malabsorption syndrome.",
        "  Patients who have received more than two cycles of chemotherapy for the metastatic disease.",
        "  Patients Her2 + per FISH \u00f3 +++ Immunohistochemistry"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Progression",
        "  Time to Progression (TTP) is defined as the time (in months) from the moment the patient starts the study treatment to the date of progressive disease. That is, a patient has an event is she progresses or dies due to progressive disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).",
        "  Time frame: After 1 year from the treatment start day.",
        "Results 1: ",
        "  Arm/Group Title: Arm A (Cint)",
        "  Arm/Group Description: Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity.",
        "  Overall Number of Participants Analyzed: 72",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  8.68        (6.55 to 11.05)",
        "Results 2: ",
        "  Arm/Group Title: Arm B (Ccont)",
        "  Arm/Group Description: Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity.",
        "  Overall Number of Participants Analyzed: 84",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  6.84        (6.02 to 8.06)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 13/95 (13.68%)",
        "  Neutrophils/granulocytes (ANC/AGC)1/95 (1.05%)",
        "  Ventricular arrhythmia1/95 (1.05%)",
        "  Diarrhea6/95 (6.32%)",
        "  Obstruction1/95 (1.05%)",
        "  Mucositis/stomatitis1/95 (1.05%)",
        "  Febrile neutropenia2/95 (2.11%)",
        "  Infection with unknown ANC0/95 (0.00%)",
        "  Dizziness1/95 (1.05%)",
        "  Renal failure0/95 (0.00%)",
        "Adverse Events 2:",
        "  Total: 4/97 (4.12%)",
        "  Neutrophils/granulocytes (ANC/AGC)1/97 (1.03%)",
        "  Ventricular arrhythmia0/97 (0.00%)",
        "  Diarrhea0/97 (0.00%)",
        "  Obstruction0/97 (0.00%)",
        "  Mucositis/stomatitis0/97 (0.00%)",
        "  Febrile neutropenia0/97 (0.00%)",
        "  Infection with unknown ANC1/97 (1.03%)",
        "  Dizziness0/97 (0.00%)",
        "  Renal failure1/97 (1.03%)"
    ]
}